COVID-19 and Private Health Insurance Coverage: Frequently Asked Questions

May 15, 2020 – April 9, 2021 R46359

COVID-19 and Private Health Insurance
April 9, 2021
Coverage: Frequently Asked Questions
Vanessa C. Forsberg
There is considerable congressional interest in understanding private health insurance coverage
Analyst in Health Care
of health benefits related to the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. This
Financing
report addresses frequently asked questions about private health insurance covered benefits and

consumer cost sharing related to COVID-19 testing, treatment, and vaccination. It explains
relevant legislation enacted in 2020, references existing federal requirements, discusses

applicable administrative guidance, and notes state and private-sector actions.
Federal and state health insurance requirements may relate to covered benefits and consumer cost sharing, among many other
topics. These requirements can vary by coverage type (i.e., individual coverage, fully insured small- and large-group
coverage, and self-insured plans). Covered benefits, consumer costs, and other plan features may vary by plan within each
type of coverage, subject to applicable federal and state requirements.
The following bullets summarize federal requirements related to coverage and cost sharing (which includes deductibles,
coinsurance, and copayments) of COVID-19 testing, treatment, and vaccination. Additional details are addressed in the
report, including the applicability of the requirements to different types of plans; whether the coverage requirements apply
even when furnished by out-of-network providers; whether plans are allowed to impose prior authorization or other medical
management techniques; and the applicable dates of any coverage requirements.
 COVID-19 Testing. The Families First Coronavirus Response Act (FFCRA; P.L. 116-127), as amended by
the Coronavirus Aid, Relief, and Economic Security Act (CARES Act; P.L. 116-136), requires most private
health insurance plans to cover COVID-19 testing, administration of the test, and related items and
services, as defined by the acts. This coverage must be provided without consumer cost sharing.
 COVID-19 Treatment. There are no federal requirements that specifically require coverage of COVID-19
treatment. However, the existing federal requirement that certain plans cover a set of 10 categories of
essential health benefits (EHB) is potentially relevant to coverage of COVID-19 treatment items and
services, depending on state and plan variation with regard to implementation of this requirement. Even
where treatment items and services are required to be covered as EHB, cost sharing could apply.
 COVID-19 Vaccination. For a nationwide vaccination campaign, the federal government has purchased,
and is making available to providers at no cost, all COVID-19 vaccines and certain related supplies. Given
this federal purchase, applicable plans still must cover providers’ vaccine administration fees without
consumer cost sharing. This is related to a CARES Act requirement for most plans to cover recommended
COVID-19 vaccines without consumer cost sharing. Most plans also must cover, without cost sharing,
other COVID-19 preventive services that may be recommended, as specified by the CARES Act.
Some states also have announced relevant requirements on the plans they regulate, and some insurers have reported that they
will cover certain relevant benefits. Several organizations are tracking these announcements, as noted in this report.
Congressional Research Service (CRS) experts on other topics related to private health insurance and COVID-19, including
types of plans and coverage of benefits not addressed in this report, are listed in the Appendix for the benefit of
congressional clients. For information on other COVID-19 issues, congressional clients can access the CRS Coronavirus
Disease resources page at https://www.crs.gov/resources/coronavirus-disease-2019.
Congressional Research Service

link to page 19 link to page 19 FAQ: COVID-19 and Private Health Insurance Coverage

Introduction
The Coronavirus Disease 2019 (COVID-19) pandemic continues in 2021. As private health
insurance is the predominant source of health coverage in the United States,1 there is considerable
congressional interest in understanding private health insurance coverage of health benefits
related to COVID-19 diagnosis, treatment, and prevention.
This report addresses frequently asked questions about covered benefits and consumer cost
sharing related to COVID-19 testing, treatment, and vaccination. It explains relevant legislation
enacted in 2020, references existing federal requirements, discusses applicable administrative
guidance, and notes state and private-sector actions. It begins with background information on
types and regulation of private health insurance plans.
The Families First Coronavirus Response Act (FFCRA; P.L. 116-127)2 requires specified types of
private health insurance plans to cover COVID-19 testing, administration of the test, and related
items and services, without consumer cost sharing. The Coronavirus Aid, Relief, and Economic
Security Act (CARES Act; P.L. 116-136)3 further addresses private health insurance coverage of
COVID-19 testing, and requires coverage of COVID-19 vaccines and other preventive services
without cost sharing, if they are recommended by specified federal entities. Given the subsequent
federal purchase of al COVID-19 vaccines and certain related supplies, applicable plans stil
must cover providers’ vaccine administration fees without consumer cost sharing. There are no
federal requirements that specifical y require coverage of COVID-19 treatment services.
However, one or more existing federal requirements are potential y relevant, as discussed in this
report. Some states also have announced requirements related to covered benefits and consumer
costs, and some insurers have reported that they wil voluntarily cover certain relevant benefits.
This report discusses most U.S. private health insurance plans’ coverage of health care items and
services related to COVID-19, but it general y does not discuss the delivery of those services,
insurers’ payments to health care providers, or private health insurance coverage of other benefits.
The Appendix lists Congressional Research Service (CRS) analysts who can discuss with
congressional clients other topics of interest related to private health insurance and COVID-19,
including types of plans and coverage of benefits not addressed in this report. Also beyond the
scope of this report are public health coverage programs (e.g., Medicare); the domestic and
international public health responses to COVID-19; and economic, human services, and other
nonhealth issues. For further information on these topics, congressional clients can access the
CRS Coronavirus Disease 2019 resources page at https://www.crs.gov/resources/coronavirus-
disease-2019.
The information in this report is current as of its publication date and may be superseded by
subsequent congressional or administrative action. Congressional clients may contact the report
author and/or the experts listed in the Appendix for questions about further developments. In

1 For more information and coverage estimates, see CRS In Focus IF10830, U.S. Health Care Coverage and Spending.
2 H.R. 6201 was signed into law as the Families First Coronavirus Response Act (FFCRA; P.L. 116-127) on March 18,
2020. See CRS Report R46316, Health Care Provisions in the Fam ilies First Coronavirus Response Act, P.L. 116 -127,
for more information about the health provisions in the act.
3 H.R. 748 was signed into law as the Coronavirus Aid, Relief, and Economic Security Act (CARES Act; P.L. 116-136)
on March 27, 2020. See CRS Report R46334, Selected Health Provisions in Title III of the CARES Act (P.L. 116 -136)
for more information about the health provisions in the act.
Congressional Research Service
1

link to page 19 link to page 19 FAQ: COVID-19 and Private Health Insurance Coverage

addition, Centers for Medicare & Medicaid Services (CMS) guidance related to private health
insurance and COVID-19 is compiled on its website.4
Background on Private Health Insurance
The private health insurance market includes both the group market (largely made up of
employer-sponsored insurance) and the nongroup market (commonly referred to as the individual
market, which includes plans directly purchased from an insurer). The group market is divided
into smal - and large-group market segments; a small group is typical y defined as a group of up
to 50 individuals (e.g., employees), and a large group is typical y defined as one with 51 or more
individuals.5 Employers and other group health plan sponsors may purchase coverage from an
insurer in the smal - and large-group markets (i.e., they may fully insure). Sponsors may instead
finance coverage themselves (i.e., they may self-insure).6 The individual and smal -group markets
include plans sold on and off the individual and smal -group health insurance exchanges,
respectively.7
Covered benefits, consumer costs, and other plan features may vary by plan, subject to applicable
federal and state requirements. The federal government may regulate al the coverage types noted
above (i.e., individual coverage, fully insured smal - and large-group coverage, and self-insured
group plans), and states may regulate al but self-insured group plans. Federal and state
requirements may vary by coverage type.8
This report focuses on private-sector plans explained above.9 There are some variations of these
coverage types, and there are other types of private health coverage arrangements, which may or
may not be subject to the requirements discussed in this report, or for which there may be other
policy questions related to COVID-19. These other coverage types are out of the scope of this
report, but a number of them are identified in the Appendix, along with resources for further
information.
One coverage variation, grandfathered plans, is included in this report because it is explicitly
referenced in legislation relevant to COVID-19 and private health insurance coverage.
Grandfathered plans are individual or group plans in which at least one individual was enrolled as

4 See Centers for Medicare & Medicaid Services (CMS), T he Center for Consumer Information and Insurance
Oversight (CCIIO), “ Coronavirus Disease 2019 (COVID-19) Guidance,” accessed March 22, 2021, at
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs#COVID-19.
5 In general, for purposes of health insurance requirements, small groups are those with 50 or fewer individuals (e.g.,
employees). States can also define them as having 100 or fewer individuals. T he definition of large group is 51 or more
individuals, or 101 or more individuals, depending on the definition of small group.
6 Employers and other plan sponsors may purchase coverage from state-licensed insurers and offer it to their employees
or other group members. Employers and other plan sponsors that obtain health insurance plans in this way are referred
to as being fully insured. Employers or other plan sponsors that self-insure set aside funds to pay for health benefits
directly, and they bear the risk of covering medical expenses generated by the individuals covered under the self-
insured plan.
7 T he health insurance exchanges are virtual marketplaces in which consumers and small businesses can shop for and
purchase private health insurance coverage. For more information, see CRS Report R44065, Overview of Health
Insurance Exchanges.
8 For more information about types of plans and regulation of them, see CRS Report R45146, Federal Requirements on
Private Health Insurance Plans.
9 In terms of group coverage, this report focuses on group plans sponsored by private-sector employers and other
sponsors. Some information in this report may also apply to federal, state, and local government employee group plans.
See the Appe ndix for resources on federal employee and other types of government plans.
Congressional Research Service
2

link to page 7 link to page 6 FAQ: COVID-19 and Private Health Insurance Coverage

of enactment of the Patient Protection and Affordable Care Act (ACA; P.L. 111-148, as amended),
and which continue to meet certain criteria.10 Plans that maintain their grandfathered status are
exempt from some, but not al , federal requirements.
Another type of coverage, short-term, limited duration insurance (STLDI or STLD plans), is also
included in this report, because it is explicitly excluded from a coverage definition cited by
relevant legislation. STLDI is coverage, general y sold in the individual market, which meets
certain definitional criteria. The statutory definition of “individual health insurance coverage”
excludes STLDI; thus, STLDI is exempt from complying with al federal health insurance
requirements applicable to individual health insurance plans.11
FAQ: COVID-19 Covered Benefits and Cost Sharing
The remainder of this report addresses private health insurance coverage of COVID-19 testing,
treatment, and vaccination. Where there are federal requirements related to such coverage, it is
useful to understand the following:
 Is the service or item required to be covered? If so, is cost sharing al owed? In
general, private health insurance cost sharing includes deductibles, coinsurance,
and copayments.12
 Are plans al owed to impose prior authorization or other medical management
requirements? For example, some insurers require enrollees to obtain prior
authorization from the insurer for routine hospital inpatient care, and/or require
that primary care physicians provide approval or referrals for specialty care, as a
condition for covering the care.13
 Does the coverage requirement depend on how or where the service or item is
furnished (e.g., by an in-network versus out-of-network provider)? Under private
insurance, benefit coverage and consumer cost sharing is often contingent upon
whether the service or item is furnished by a provider that the insurer has
contracted with (i.e., whether that provider is in network for a given plan). In
instances where a contract between an insurer and provider does not exist, the
provider is considered out of network.14
 When is the coverage requirement in effect?
 What types of plans are subject to the coverage requirement?
To the extent that information is available, these issues are addressed with regard to private health
insurance coverage of COVID-19 testing, treatment, and vaccination. Table 1 summarizes key
information.

10 T he ACA was enacted on March 23, 2010. For more information about grandfathered plans, see CRS Report
R46003, Applicability of Federal Requirem ents to Selected Health Coverage Arrangem ents.
11 See 42 U.S.C. §300gg-91(b)(5). For more information about ST LDI, see the report cited in footnote 10.
12 A deductible is the amount an insured consumer pays for covered health care services before coverage begins (with
exceptions). Coinsurance is the share of costs, figured in percentage form, an insured consumer pays for a covered
health service. A copaym ent is the fixed dollar amount an insured consumer pays for a covered health service.
13 For more information, see the appendix of CRS Report RL32237, Health Insurance: A Primer.
14 For more information, see the background section of CRS Report R46116, Surprise Billing in Private Health
Insurance: Overview and Federal Policy Considerations.
Congressional Research Service
3

link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8 link to page 8
Table 1. Applicability of Federal COVID-19 Coverage Requirements to Private Health Insurance Plans
Group Marketc
Medical
Coverage and Cost-Sharing
Management
Applies
Self-
Individual
Authority
Requirements
Approaches
Out-of-
Time Frame
Fully Insurede
Insuredf
Marketd
Allowed?a
Network?b
Large
Small
Groupg
Groupg
Testing
FFCRA §6001
COVID-19 testing, administration of the test,
FFCRA enactment
(as amended by
and related items and services, as defined, must Prohibited.
Yes.
(March 18, 2020)
✓ (+GF)i
✓ (+GF)i
✓ (+GF)i
✓ (+GF)i
CARES Act §3201) be covered without cost sharing.
through declared
COVID-19 PHE.h
Treatment
42 U.S.C. §18022;
EHB requirements may apply to coverage of
Permanent; existed
CMS March 5,
COVID-19 treatment services, subject to state
Al owed; may
2020, and March
and plan variation. Cost sharing is possible and
vary by plan.
No.
prior to COVID-19
N.A.
✓
N.A.
✓
12, 2020, guidancej may vary by plan.
pandemic.
Where EHB requirements are applicable,
Permanent; existed
42 U.S.C. §18022
certain other requirements are also applicable,
N.A.
No.
prior to COVID-19
✓k
such as the limit on annual out-of-pocket

✓
✓k
✓
pandemic.
spending on EHB benefits.
Vaccination
COVID-19 vaccination items and services, and
15 business days after
other COVID-19 preventive items and services,
Only during
ACIP or USPSTF
CARES Act §3203; must be covered without cost sharing if
Al owed; may
declared
recommendation;
November 2020
recommended by ACIP or the USPSTF.m
general coverage
✓
✓
✓
✓
IFRl
Given the federal purchase of al vaccines, plans vary by plan.
COVID-19
requirements not
must stil cover vaccine administration fees
PHE.
limited to declared
without cost sharing.
COVID-19 PHE.
Source: CRS analysis of relevant legislation, statute, regulation, and guidance.
Notes: Checkmark (✓) = requirement is applicable to that plan type. The variation (✓+GF) = requirement also is applicable to grandfathered plans; see table note (i). N.A.
= requirement is not applicable to that plan type. None of these requirements applies to short-term, limited-duration insurance (STLDI); see table note (d). ACIP =
Advisory Committee on Immunization Practices; CARES Act = Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136); EHB = essential health benefits;
FFCRA = Families First Coronavirus Response Act (P.L. 116-127); PHE = COVID-19 public health emergency; see table note (h); USPSTF = United States Preventive
Services Task Force. The requirements listed in the table do not comprise a comprehensive list of al federal requirements that apply to al health plans.
CRS-4

link to page 16
a. An example of a medical management technique that insurers may use, as al owed, is requiring enrol ees to obtain prior authorization from the insurer for coverage
of certain services. For more information, see the appendix of CRS Report RL32237, Health Insurance: A Primer.
b. Al requirements apply to services or items furnished in network. Under private insurance, benefit coverage and consumer cost sharing are often contingent upon
whether a service or item is furnished by a provider that the insurer has contracted with (i.e., whether that provider is in network for a given plan). In instances
where a contract between an insurer and provider does not exist, the provider is considered out of network. For more information, see the background section of
CRS Report R46116, Surprise Bil ing in Private Health Insurance: Overview and Federal Policy Considerations.
c. Health insurance may be provided to a group of people who are drawn together by an employer or other organization, such as a trade union. Such groups general y
are formed for purposes other than obtaining insurance, such as employment. When insurance is provided to a group, it is referred to as group coverage or group
insurance. In the group market, the entity that purchases health insurance on behalf of a group is referred to as the plan sponsor.
d. Consumers who are not associated with a group can obtain health coverage by purchasing it directly from an insurer in the ind ividual (or nongroup) health
insurance market. Although STLDI is a type of coverage general y sold in the individual market, the statutory definition of ind ividual health insurance coverage
excludes STLDI. Thus, no federal health insurance requirements on individual health insurance plans apply to STLDI.
e. A ful y insured health plan is one in which the plan sponsor purchases health coverage from a state-licensed insurer; the insurer assumes the risk of paying the
medical claims for benefits covered under the health plan of the sponsor’s enrol ed members.
f.
Self-insured plans refer to health coverage that is provided directly by the organization sponsoring coverage for its members (e.g., a firm providing health benefits to
its employees). Such organizations set aside funds and pay for health benefits directly. Under self-insurance, the organization bears the risk for covering medical
claims. In general, the size of a self-insured employer does not affect the applicability of federal requirements.
g. In general, for purposes of health insurance requirements, smal groups are those with 50 or fewer individuals (e.g., employees). States can also define them as having
100 or fewer individuals. The definition of large group is 51 or more individuals, or 101 or more individuals, depending on t he definition of smal group.
h. Some FFCRA and CARES Act coverage requirements are contingent upon the declaration of the COVID-19 public health emergency. This was declared by the
Secretary of Health and Human Services (HHS) on January 31, 2020, effective as of January 27, pursuant to Section 319 of the Public Health Service Act. Hence, the
emergency period began on January 27, 2020, and remains in effect as long as the declaration, or any renewal of it, is in eff ect. See “Duration of Emergency Period”
in CRS Report R46316, Health Care Provisions in the Families First Coronavirus Response Act, P.L. 116-127; and HHS, Assistant Secretary for Preparedness and Response,
“Public Health Emergency Declarations,” at https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.
i.
Grandfathered plans are individual or group plans in which at least one individual was enrol ed as of enactment of the Patient Prot ection and Affordable Care Act
(ACA; P.L. 111-148, as amended), and which continue to meet certain criteria. Plans that maintain their grandfathered status are exempt from some federal
requirements. However, FFCRA specifies that its COVID-19 testing coverage requirements do apply to grandfathered plans.
j.
Centers for Medicare & Medicaid Services (CMS), “FAQs on Essential Health Benefit Coverage and the Coronavirus (COVID-19),” March 12, 2020.
CMS, “Information Related to COVID–19 Individual and Smal Group Market Insurance Coverage,” March 5, 2020.
k. Self-insured plans and plans offered in the large-group market must comply with this requirement even though they are not required to cover the EHB. HHS has
indicated that such plans must use a permissible definition of EHB to determine whether they comply with the requirement.
l.
Departments of Labor, HHS, and the Treasury, “Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency,” 85 Federal
Register 71142, November 6, 2020, at https://www.federalregister.gov/documents/2020/11/06/2020-24332/additional-policy-and-regulatory-revisions-in-response-to-
the-covid-19-public-health-emergency.
m. See “Are Plans Required to Cover COVID-19 Vaccination?” regarding COVID-19 vaccines available as of the date of this report. Cost sharing for office visits
associated with applicable vaccinations and other preventive services may or may not be al owed. In general, this depends on whether the preventive service or item
was the primary purpose of the visit, and whether the service or item was bil ed or tracked separately from the office visit. See 45 C.F.R. §147.130(a)(2).
CRS-5

FAQ: COVID-19 and Private Health Insurance Coverage

Are Plans Required to Cover COVID-19 Testing?
FFCRA and CARES Act
Prior to the enactment of the FFCRA, there were no federal requirements specifical y mandating
private health insurance coverage of items or services related to COVID-19 testing.
Section 6001 of the FFCRA, as amended, requires most private health insurance plans to cover
COVID-19 testing, administration of the test, and related items and services, as defined in the act.
The coverage must be provided without consumer cost sharing, including deductibles,
copayments, or coinsurance. Prior authorization or other medical management requirements are
prohibited.15 The Department of Labor (DOL), Department of Health and Human Services
(HHS), and Treasury issued FAQ documents on April 11, 2020,16 June 23, 2020,17 and February
26, 2021,18 (hereinafter “Tri-Agency FAQ 42,” “Tri-Agency FAQ 43,” and “Tri-Agency FAQ
44,” respectively) on the private health insurance coverage requirements in FFCRA and the
CARES Act.19
Types of Tests, Related Items and Services, and Testing Settings
FFCRA Section 6001(a)(1), as amended by the CARES Act Section 3201, describes the types of
tests that must be covered, along with the administration of such tests. Together, the acts require
coverage of in-vitro diagnostic tests (as defined in Food and Drug Administration [FDA]
regulation)20 that detect SARS-CoV-2 or diagnose the virus that causes COVID-19 and are
approved, cleared, or authorized for marketing by the agency or being marketed or clinical y used
pursuant to an al owed flexibility in FDA guidance. The acts did not explicitly state whether this
included serology testing.21 The Tri-Agency FAQ 42 interpreted the coverage requirement as
applying to diagnostic (i.e., molecular and antigen) and serological (i.e., antibody) tests.
Together, the acts, as interpreted by the agencies through guidance, also require coverage without
cost sharing of

15 See the introduction to this section regarding cost sharing and prior authorization requirements.
16 Department of Labor (DOL), HHS, and T reasury, “ FAQS About Families First Coronavirus Response Act and
Coronavirus Aid, Relief, and Economic Security Act Implementation, Part 42 ,” April 11, 2020, at
https://www.cms.gov/files/document/FFCRA-Part -42-FAQs.pdf. Hereinafter referred to as T ri-Agency FAQ 42.
17 DOL, HHS, and T reasury, “ FAQS About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and
Economic Security Act Implementation, Part 43,” June 23, 2020, at https://www.cms.gov/files/document/FFCRA-Part -
43-FAQs.pdf. Hereinafter referred to as T ri-Agency FAQ 43.
18 DOL, HHS, and T reasury, “FAQS About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and
Economic Security Act Implementation, Part 44,” February 26, 2021, at https://www.cms.gov/files/document/faqs-part -
44.pdf. Hereinafter referred to as T ri-Agency FAQ 44.
19 For a discussion of the agencies’ implementation authority and the force of law of these documents, see “Are Plans
Required to Cover T esting for Public Health Surveillance or Employment Purposes?” in CRS Report R46481, COVID-
19 Testing: Frequently Asked Questions.
20 21 C.F.R. §809.3(a).
21 Although both serology tests and molecular and antigen diagnostic tests meet the regulatory definition of “in vitro
diagnostic,” applicability to serology testing was not clear based only on the statutory language as it refers to detection
and identification of the virus. Serology testing does not detect or identify the virus; rather, it detects antibodies. For
more information, see “What Are the Different T ypes of COVID-19 T ests?” in CRS Report R46481, COVID-19
Testing: Frequently Asked Questions.
Congressional Research Service
6

link to page 14 FAQ: COVID-19 and Private Health Insurance Coverage

items and services furnished to an individual during [specified types of visits; discussed
below] that result in an order for or administration of [an applicable COVID-19 test; see
above], but only to the extent such items and services relate to the furnishing or
administration of such product or to the evaluation of such individual for purposes of
determining the need of such individual for such product.22
Per an example provided in guidance,
if the individual’s attending provider determines that other tests (e.g., influenza tests, blood
tests, etc.) should be performed during a visit … to determine the need of such individual
for COVID-19 diagnostic testing, and the visit results in an order for, or administration of,
COVID-19 diagnostic testing, the plan or issuer must provide coverage for the related tests
under section 6001(a) of the FFCRA.23
In addition, consumers must not face cost-sharing for “facility fees” or other fees, to the extent
they are related to COVID-19 testing or related items and services that are required to be covered
under FFCRA Section 6001.24
The coverage requirements do not apply to any services or items furnished at a testing visit that
are not related to COVID-19 (e.g., if someone received testing or treatment for an unrelated
condition at the same visit). In addition, the law and guidance do not explicitly address coverage
and cost-sharing for the “related” items and services discussed above if the individual does not
ultimately receive the test.25 The requirements also do not encompass treatment for il nesses
associated with COVID-19.26
Per FFCRA Section 6001(a)(2), the coverage requirements apply to the specified items and
services, discussed above, when furnished at visits including to health care provider offices
(including in-person and telehealth visits), urgent care centers, and emergency rooms. Per the Tri-
Agency FAQ 42, the requirements also apply at “nontraditional” settings, “including drive-
through screening and testing sites where licensed health care providers are administering
COVID-19 diagnostic testing.”27
In addition, guidance indicates that the coverage requirements apply to at-home COVID-19 tests,
including at-home swab kits that may be sent to a lab for processing, when such tests are “ordered
by an attending health care provider who has determined that the test is medical y appropriate for
the individual,” as specified in guidance.28

22 FFCRA §6001(a)(2). Also see the T ri-Agency FAQ 42, including questions five, six, and eight ; and T ri-Agency
FAQ 44, question five.
23 T ri-Agency FAQ 42, question five.
24 For more information, see the T ri-Agency FAQ 43, question seven, including its footnote 16.
25 Per the T ri-Agency FAQ 42, question five, the coverage of related items and services is required when “the visit
results in an order for, or administration of, COVID-19 diagnostic testing.” T his language also appears in FFCRA
Section 6001(a)(2). T he statute and guidance do not explicitly address whether the coverage requirements apply if an
individual receives the related items and services, even for purposes of determining the need for COVID -19 testing, but
does not actually receive a COVID-19 test. Other federal and/or state requirements could be applicable.
26 See “Are Plans Required to Cover COVID-19 T reatment?” in this report for more information.
27 See T ri-Agency FAQ 42, question eight, regarding “nontraditional” visits. T ri-Agency FAQ 44, questions three and
four, provide additional details. Also see FAQ 42, question 13, for more information about telehealth visits.
28 T ri-Agency FAQ 43, question four. Also see question three regarding “attending providers.”
Congressional Research Service
7

link to page 5 FAQ: COVID-19 and Private Health Insurance Coverage

Timing of Requirements and Applicability to Different Types of Plans
The private health insurance coverage requirements in FFCRA apply only to the specified items
and services that are furnished during the COVID-19 public health emergency period described in
that act, as of the date the FFCRA was enacted (March 18, 2020).29
These requirements apply to individual health insurance coverage, fully insured smal - and large-
group coverage, and self-insured group plans30 including grandfathered individual or group plans,
which are exempt from certain other federal private health insurance requirements. Per the
definition of individual health insurance coverage cited in the act, the requirements do not apply
to STLDI.31
Prohibition of Medical Management Requirements
Following enactment of FFCRA Section 6001, questions arose about the parameters of its testing
requirements and its prohibition on “prior authorization or other medical management
requirements,” including whether plans must pay for testing that is not mainly intended for the
clinical or treatment needs of individual patients.32 These questions centered on whether Section
6001 compels plans to cover testing for other reasons, such as public health surveil ance or
workplace health purposes. There also have been questions about coverage in general of testing
for asymptomatic individuals with no known or suspected recent exposure to COVID-19.
Medical management was not defined in statute at the time FFCRA was enacted. However, the
Consolidated Appropriations Act, 2021 (P.L. 116-260), enacted in December 2020, contained
several references to medical management techniques in its provisions related to surprise bil ing,
such as this parenthetical: “a medical management technique (including concurrent review, prior
authorization, and step-therapy or fail-first protocols).”33 In addition, “reasonable medical
management techniques” are referenced in existing federal regulations as techniques that plans
may use to “determine the frequency, method, treatment, or setting for an item or service.”34

29 Some FFCRA and CARES Act coverage requirements are contingent upon the declaration of the COVID-19 public
health emergency. T his was declared by the HHS Secretary on January 31, 2020, effective as of January 27, pursuant to
§319 of the Public Health Service Act (PHSA). Hence, the emergency period began on January 27, 2020, and remains
in effect as long as the declaration, or any renewal of it, is in effect. See “Duration of Emergency Period” in CRS
Report R46316, Health Care Provisions in the Fam ilies First Coronavirus Response Act, P.L. 116 -127, and HHS,
Assistant Secretary for Preparedness and Response, “Public Health Emergency Declarations,” at https://www.phe.gov/
emergency/news/healthactions/phe/Pages/default.aspx.
30 T he requirements technically are applicable to group health plans and health insurers offering individual and group
health insurance coverage. In this report, references to plans include applicable plans and insurers.
31 See “Background on Private Health Insurance” regarding these types of plans, including grandfathered plans and
ST LDI.
32 See, for example, Letter from the National Association of Insurance Commissioners (NAIC) and the Center for
Insurance Policy and Research, to Alex Azar, HHS Secretary, and Seema Verma, CMS Administrator, at
https://www.naic.org/documents/government_relations_letter_to_azar.pdf.
33 Consolidated Appropriations Act, 2021 (P.L. 116-260), §111 of Division BB, adding §2799A-1(f)(1)(F) to the
PHSA. Also see definitions of m edical m anagement system s (“ Systems designed to ensure that members receive
appropriate [covered] health care services”) and related terms in Box 2-1 and elsewhere in the report: Institute of
Medicine (now National Academies of Medicine), Essential Health Benefits: Balancing Coverage and Cost, 2012, at
https://doi.org/10.17226/13234.
34 45 C.F.R. §147.130(a)(4). These regulations address federal requirements on private health insurance coverage of
certain preventive services (discussed later in this report).
Congressional Research Service
8

FAQ: COVID-19 and Private Health Insurance Coverage

Although these federal references are informative, their direct relevance to FFCRA Section 6001
is unclear. Administrative guidance has been issued on related questions, however.
The Tri-Agency FAQ 42 interpreted FFCRA Section 6001 as compel ing plans to cover testing
only “when medical y appropriate for the individual, as determined by the individual’s attending
healthcare provider in accordance with accepted standards of current medical practice.”35 The
guidance did not further outline the circumstances in which COVID-19 tests were “medical y
appropriate”; however, under the agencies’ interpretation, the availability of covered testing
appeared contingent upon a medical decision by a health care provider responsible for providing
care to a specific patient.
The Tri-Agency FAQs 43 and 44 provided additional information. Coverage of testing is required
for asymptomatic individuals, whether or not they have had known or suspected recent exposure
to SARS-CoV-2.36 The coverage requirements apply each time an individual receives a diagnostic
test for COVID-19, “provided that the tests are diagnostic and medical y appropriate for the
individual, as determined by an attending health care provider in accordance with current
accepted standards of medical practice.”37 FAQ 43 suggests that providers “consult guidance
issued by the CDC, as wel as state, tribal, territorial, and local health departments or professional
societies, when determining whether diagnostic testing is appropriate for a particular
individual.”38 FAQ 44 further states,
State and local public health authorities retain the authority to direct providers to limit
eligibility for testing based on clinical risk or other criteria to manage testing supplies and
access to testing. Responsibility for implementing such state or local limits on testing fals
on attending health care providers, not on plans and issuers. Plans and issuers may not use
such criteria to deny (or impose cost sharing on) a claim for COVID-19 diagnostic testing.39
However, per FAQ 43, plans are not required to cover COVID-19 testing “for general workplace
health and safety (such as employee ‘return-to-work’ programs), for public health surveil ance for
SARS-CoV-2, or for any other purpose not primarily intended for individualized diagnosis or
treatment of COVID-19 or another health condition.”40 This guidance was maintained in FAQ 44,
where questions one and two explain that although plans are required to cover testing for
individuals as explained above (e.g., including for asymptomatic individuals), plans are not
similarly required to cover testing for “groups of asymptomatic employees or individuals with no
known or suspected recent exposure to COVID-19” (emphasis added).
Out-of-Network Testing
FFCRA does not specify whether its coverage requirements apply when the test is furnished by an
out-of-network provider. However, Section 3202 of the CARES Act addresses insurer payments

35 T ri-Agency FAQ 42, question six.
36 Per T ri-Agency FAQ 43, question five, coverage of testing for asymptomatic individuals was only required if the
individuals had known or suspected exposure. T his was revised by T ri-Agency FAQ 44, question one, which states that
the known or suspected exposure is not required for coverage of individuals’ testing.
37 T ri-Agency FAQ 43, question six. Also see question three regarding “attending providers.”
38 Ibid.
39 T ri-Agency FAQ 44, question one.
40 T ri-Agency FAQ 43, question five.
Congressional Research Service
9

link to page 11 FAQ: COVID-19 and Private Health Insurance Coverage

to in-network and out-of-network providers. In addition, the Tri-Agency FAQ 42 clarifies that the
FFCRA coverage requirements apply both in network and out of network.41
For further discussion of coverage and provider reimbursement requirements applicable to out-of-
network testing and “balance bil ing” by out-of-network providers, see “What Coverage and
Provider Reimbursement Requirements Apply to Out-of-Network Testing?” and “Are Out-of-
Network Providers Al owed to Balance Bil Patients for COVID-19 Testing and Other Related
Items and Services?” in CRS Report R46481, COVID-19 Testing: Frequently Asked Questions.
State and Private-Sector Actions
Both before and after the enactment of FFCRA, some states announced coverage requirements,
and some insurers clarified or expanded their policies regarding coverage of COVID-19 testing,
among other services.42 However, states cannot regulate self-insured plans, and insurer
announcements do not necessarily apply to those plans. FFCRA does apply to self-insured group
plans in addition to the other plan types discussed above.
To the extent that state requirements about or plans’ voluntary coverage of COVID-19 testing did
not extend as far as FFCRA and CARES Act requirements, the federal laws supersede them.
However, state requirements and plans’ voluntary coverage may exceed applicable federal
requirements, as long as they do not prevent the implementation of any federal requirements.43
A state or local department of health or other administrative agency may announce requirements
or guidelines regarding testing certain populations or testing for certain public health purposes.
However, this does not necessarily mean insurers in that state are required to cover such testing,
although that would be the case if the state department of insurance or other relevant agency also
requires such coverage or if federal requirements are applicable. This is because it is the state
department of insurance, not the state department of health, which regulates insurance. However,
see “Prohibition of Medical Management Requirements” regarding Tri-Agency guidance to plans
on deferring to providers’ implementation of any state and local testing limits.
Even though federal law now requires most plans to cover specified COVID-19 testing services
without cost sharing, it may be useful for consumers to contact their insurers or plan sponsors to
understand their coverage. Subject to applicable federal and state requirements, coverage of the
COVID-19 test and related services and items may vary by plan.

41 T ri-Agency FAQ 42, question seven. Furthermore, question nine of the T ri-Agency FAQ 43 clarifies that out-of-
network providers are generally precluded from directly billing a patient for the difference between provider’s charge
for COVID-19 testing and the amount reimbursed by the health plan (i.e., balance billing). However, a provider is not
prevented from balance billing for other items and services unless there is an applicable state law or other prohibition
(e.g., pursuant to the terms of the Provider Relief Fund). For background on this funding, see CRS Insight IN11438,
The COVID-19 Health Care Provider Relief Fund.
42 Several organizations have been tracking these announcements by states and/or insurers. See, for example, the NAIC
“Life and Health” resource, updated December 10, 2020, at https://content.naic.org/naic_coronavirus_info.htm, and the
Association of Health Insurance Plans (AHIP), “ Healt h Insurance Providers Respond to Coronavirus (COVID-19),”
updated March 22, 2021, at https://www.ahip.org/health-insurance-providers-respond-to-coronavirus-covid-19/. Note
that some of the states’ requirements and/or insurers’ additional coverage statements have been time-limited and may
no longer be in effect . T hese time limits generally appear to be reflected on the NAIC and AHIP sites.
43 See, for example, the introduction of the Tri-Agency FAQ 42.
Congressional Research Service
10

FAQ: COVID-19 and Private Health Insurance Coverage

Are Plans Required to Cover COVID-19 Treatment?
Essential Health Benefits Guidance on COVID-19 Coverage
Although FFCRA requires certain plans to cover specified COVID-19 testing services without
cost sharing, neither FFCRA nor the CARES Act mandates coverage of COVID-19 treatment
services. There is no federal requirement specifical y mandating private health insurance
coverage of items or services related to COVID-19 treatment. However, one or more existing
federal requirements are potential y relevant, subject to state implementation and plan variation.
There is a federal statutory requirement that certain plans cover a core set of 10 categories of
essential health benefits (EHB).44 However, states, rather than the federal government, general y
specify the benefit coverage requirements within those categories. Current regulation al ows each
state to select an EHB-benchmark plan. The benchmark plan serves as a reference plan on which
plans subject to EHB requirements must substantial y base their benefits packages. Because states
select their own EHB-benchmark plans, there is considerable variation in EHB coverage from
state to state.45
On March 5, 2020, and March 12, 2020, CMS issued guidance addressing the potential relevance
of EHB requirements to coverage of COVID-19 treatment, among other benefits, subject to
variation in states’ EHB-benchmark plan designations.46 According to the March 12 document,
“al 51 EHB-benchmark plans currently provide coverage for the diagnosis and treatment of
COVID-19” (emphasis added), but coverage of specific benefits within the 10 categories of EHB
(e.g., hospitalization, laboratory services) may vary by state and by plan.
The March 12, 2020, document suggests that coverage of medical y necessary hospitalizations
would include coverage of medical y necessary isolation and quarantine during the hospital
admission, subject to state and plan variation. Quarantine in other settings, such as at home, is not
a medical benefit. The document notes, “however, other medical benefits that occur in the home
that are required by and under the supervision of a medical provider, such as home health care or
telemedicine, may be covered as EHB,” subject to state and plan variation.
The March 12, 2020, document confirms that “exact coverage details and cost-sharing amounts
for individual services may vary by plan, and some plans may require prior authorization before

44 T he 10 categories of essential health benefits (EHB) are ambulatory patient services; emergency services;
hospitalization; maternity and newborn care; mental health and substance use disorder services, including behavioral
health treatment; prescription drugs; rehabilitative and habilitative services and devices; laboratory services; preventive
and wellness services and chronic disease management; and pediatric services, including oral and vision care.
45 For information about the process for defining the EHB in each state that is in place for plan years beginning before
2020, see CRS Report R44163, The Patient Protection and Affordable Care Act’s Essential Hea lth Benefits (EHB). On
April 17, 2018, HHS issued a final rule that modifies the process for defining the EHB for plan years beginning in
2020. For more information, see Department of Health and Human Services, “ HHS Notice of Benefit and Payment
Parameters for 2019,” 83 Federal Register 16930, April 17, 2018.
46 Centers for Medicare & Medicaid Services (CMS), “FAQs on Essential Health Benefit Coverage and the
Coronavirus (COVID-19),” March 12, 2020, at https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/
Downloads/EHB-Benchmark-Coverage-of-COVID-19.pdf. T he March 5, 2020, document has similar content: CMS,
“Information Related to COVID–19 Individual and Small Group Market Insurance Coverage,” at
https://www.cms.gov/files/document/03052020-individual-small-market -covid-19-fact-sheet.pdf. T hese fact sheets
each also addressed policy considerations related to private health insurance coverage of COVID-19 testing and
vaccination. T he enactment of FFCRA and the CARES Act have likely superseded much of the information in these
documents regarding such coverage of testing and vaccination, but as of the date of this report, the documents are still
relevant with regard to coverage of COVID-19 treatment.
Congressional Research Service
11

link to page 15 link to page 5 link to page 13 FAQ: COVID-19 and Private Health Insurance Coverage

these services are covered.” In other words, even where certain treatment items and services are
required to be covered as EHB in a state, cost-sharing and medical management requirements
could apply, subject to applicable federal and state requirements. In addition, cost sharing and
other coverage details may vary for services furnished by out-of-network providers.47
Individual and fully insured smal -group plans are subject to EHB requirements. Large-group
plans, self-insured plans, grandfathered plans, and STLDI are not.48
Whether or not certain treatment services are defined as EHB in a state, other state benefit
coverage requirements may be relevant to COVID-19 treatment. Plans may also voluntarily cover
benefits. See “State and Private-Sector Actions,” below.
Certain Federal Requirements Related to Cost Sharing
Other existing federal requirements are also relevant to consumer cost sharing on COVID-19
treatment services, to the extent that such treatments are covered by the consumer’s plan, and
largely to the extent that they are defined by a state as EHB.
For example, plans must comply with annual limits on consumers’ out-of-pocket spending (i.e.,
cost sharing, including deductibles, coinsurance, and copayments) on in-network coverage of the
EHB.49 If certain treatment services are defined as EHB in a state, and are furnished by an in-
network provider, consumers’ out-of-pocket costs for the plan year would be limited as discussed
below. If certain treatment services are not defined as EHB in a state, and/or are furnished by out-
of-network providers, this out-of-pocket maximum would not necessarily apply.
In 2021, the out-of-pocket limits cannot exceed $8,550 for self-only coverage and $17,100 for
coverage other than self-only. This means that once a consumer has spent up to that amount in
cost sharing on applicable in-network benefits, the plan would cover 100% of remaining
applicable costs for the plan year.
The out-of-pocket maximum applies to individual health insurance coverage, fully insured smal -
and large-group coverage, and self-insured group plans.50 The requirement does not apply to
grandfathered plans or STLDI.
State and Private-Sector Actions
As stated above, some states have announced coverage requirements related to COVID-19 testing
services and items, and some insurers have clarified or expanded their policies to include relevant
coverage.51 Some of these state and insurer statements also address coverage of treatment

47 However, see CRS Insight IN11438, The COVID-19 Health Care Provider Relief Fund regarding the prohibition on
Provider Relief Fund recipients from balance billing consumers for “ all care for a presumptive or actual case of
COVID-19.”
48 See “Background on Private Health Insurance” regarding these types of plans, including grandfathered plans and
ST LDI.
49 42 U.S.C. §18022. For more information on this requirement, and on other federal cost -sharing requirements that
may similarly be relevant (prohibition on lifetime limits and annual limits; minimum actuarial value requirements), see
CRS Report R45146, Federal Requirem ents on Private Health Insurance Plans.
50 Certain types of plans—self-insured plans and plans offered in the large-group market—must comply with this
requirement even though they are not required to cover the EHB. HHS has indicated that such plans must use a
permissible definition of EHB (including any state-selected EHB benchmark plans) to determine whether they comply
with the requirement.
51 See footnote 42 regarding organizations that are tracking such activity, and the time-limited nature of some of these
Congressional Research Service
12

FAQ: COVID-19 and Private Health Insurance Coverage

services. However, as discussed above, states cannot regulate self-insured plans, and insurer
announcements do not necessarily apply to those plans either.
Coverage, cost sharing, and the application of medical management techniques (e.g., prior
authorization) can vary by plan, subject to applicable federal and state requirements. It may be
useful for consumers to contact their insurers or plan sponsors to understand their coverage of
services and items related to COVID-19 treatment.
Are Plans Required to Cover COVID-19 Vaccination?
As of the date of this report, three COVID-19 vaccine formulations are available under
Emergency Use Authorizations granted by the Food and Drug Administration (FDA) for use in
the United States.52
For a nationwide vaccination campaign, the federal government has purchased, and is making
available to providers at no cost, al COVID-19 vaccines and certain related supplies. There are
also relevant federal coverage requirements on plans. This section provides an overview of such
federal requirements, including in the context of the federal purchase of al COVID-19 vaccines.
CARES Act and Existing Preventive Services Coverage Requirements
Prior to the enactment of the CARES Act, there were no federal requirements specifical y
mandating private health insurance coverage of items or services related to a COVID-19 vaccine.
However, per an existing federal requirement (§2713 of the Public Health Service Act [PHSA])
and its accompanying regulations, most plans must cover specified preventive health services
without cost sharing.53 This includes any preventive service recommended with an A or B rating
by the United States Preventive Services Task Force (USPSTF); or any immunization with a
recommendation by the Advisory Committee on Immunization Practices (ACIP), adopted by the
Centers for Disease Control and Prevention (CDC), for routine use for a given individual.54 These
coverage requirements apply no sooner than one year after a new or revised recommendation is
published.55
Requirements of PHSA Section 2713 apply to individual health insurance coverage, fully insured
smal - and large-group coverage, and self-insured group plans. The requirements do not apply to
grandfathered plans or to STLDI. By regulation, plans are general y not required to cover

state and/or insurer announcements.
52 See the U.S. Food and Drug Administration (FDA) page, “Emergency Use Authorization,” at https://www.fda.gov/
emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-
authorization#coviddrugs.
53 §2713 was added to the PHSA (codified at 42 U.S.C. §300gg-13) and incorporated into the Employee Retirement
Income Security Act (ERISA) and Internal Revenue Code (IRC) by the Patient Protection and Affordable Care Act
(ACA; P.L. 111-148, as amended). Regulations are at 45 C.F.R. §147.130; 29 C.F.R. §2590.715-2713; and 26 C.F.R.
§54.9815-2713.
54 For further discussion of this provision, see CRS Report R45146, Federal Requirements on Private Health Insurance
Plans. For more information about the United States Preventive Services T ask Force (USPST F) and the Advisory
Committee on Immunization Practice (ACIP), see https://uspreventiveservicestaskforce.org/uspstf/ and
https://www.cdc.gov/vaccines/acip/index.html, respectively. For more information about the definition of routine use,
see Richard Hughes IV, Reed Maxim, and Alessandra Fix, “ Vague Vaccine Recommendations May Be Leading T o
Lack Of Provider Clarity, Confusion Over Coverage,” Health Affairs, May 7, 2019.
55 Per 45 C.F.R. §147.130(b), such coverage is required “for plan years (in the individual market, policy years) that
begin on or after the date that is one year after the date the recommendation or guidelin e is issued.”
Congressional Research Service
13

FAQ: COVID-19 and Private Health Insurance Coverage

preventive services furnished out of network. They are al owed to use “reasonable medical
management” techniques, within provided guidelines. 56 Cost sharing for office visits associated
with a furnished preventive service may or may not be al owed, as specified in regulation. In
general, whether cost sharing for office visits is al owed or prohibited depends on whether the
preventive service or item was the primary purpose of the visit and whether the service or item
was bil ed or tracked separately from the office visit.57
Section 3203 of the CARES Act requires specified plans—the same types as those subject to
PHSA Section 2713—to cover COVID-19 vaccines and other COVID-19 preventive services if th
recommended by ACIP or USPSTF, respectively.58 This coverage must be provided without cost
sharing. The three vaccines currently authorized for emergency use have been recommended by
ACIP.59
As compared to existing preventive services coverage requirements, Section 3203 applies an
expedited effective date for the required COVID-19 vaccine and preventive services coverage: 15
business days after an applicable ACIP or USPSTF recommendation is published.
CARES Act Section 3203 refers to and largely mirrors PHSA Section 2713 but does not amend it.
However, an Interim Final Rule (IFR) published in November 2020 amends applicable preventive
services coverage regulations to include CARES Act COVID-19 vaccine coverage requirements,
as wel as new agency interpretations of such requirements (further discussed below).60
The statutory requirements regarding coverage of COVID-19 vaccination and other preventive
services are not time limited to the declared COVID-19 public health emergency. The November
2020 IFR’s related regulatory amendments expire at the end of the PHE.61
Private Health Insurance Coverage Given the Federal Purchase of Vaccines
In summer 2020, the federal government announced its purchase of al COVID-19 vaccines, and
some related supplies for administration of the vaccine to patients, for purposes of a nationwide
pandemic vaccination campaign.62 It is a federal crime for anyone to sel federal y purchased
COVID-19 vaccines or receive any inducement for vaccinating (i.e., it is not currently al owable
to administer or obtain the vaccine outside of the federal vaccination campaign).63

56 See 45 C.F.R. §147.130(a)(3) regarding out -of-network coverage and (a)(4) regarding reasonable medical
management.
57 See 45 C.F.R. §147.130(a)(2).
58 Unlike existing preventive services coverage requirements, COVID-19 immunization requirements are applicable
regardless of whether an ACIP recommendation is “for routine use.” See T ri-Agency FAQ 44, page 5.
59 For discussion of ACIP’s COVID-19 vaccine recommendations, see “Clinical Recommendations and Prioritization”
in CRS Report R46593, Vaccine Safety in the United States: Overview and Considerations for COVID-19 Vaccines.
60 DOL, HHS and T reasury, “ Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health
Emergency,” 85 Federal Register 71142, November 6, 2020, at https://www.federalregister.gov/documents/2020/11/
06/2020-24332/additional-policy-and-regulatory-revisions-in-response-to-the-covid-19-public-health-emergency.
Hereafter referred to as November 2020 IFR.
61 November 2020 IFR, page 71176.
62 See HHS, “U.S. Government Engages Pfizer to Produce Millions of Doses of COVID-19 Vaccine,” July 22, 2020, at
https://www.hhs.gov/about/news/2020/07/22/us-government -engages-pfizer-produce-millions-doses-covid-19-
vaccine.html. Also see HHS, “ T rump Administration Collaborates with Moderna to Produce 100 Million Doses of
COVID-19 Investigational Vaccine,” August 11, 2020, at https://www.hhs.gov/about/news/2020/08/11/trump-
administration-collaborates-with-moderna-produce-100-million-doses-covid-19-investigational-vaccine.html.
63 Centers for Disease Control and Prevention (CDC), “CDC COVID-19 Vaccination Program Provider Requirements
Congressional Research Service
14

link to page 13 FAQ: COVID-19 and Private Health Insurance Coverage

Because the federal government is providing these vaccines and supplies to providers and patients
at no cost, plans currently do not need to reimburse providers for these items. However, per the
November 2020 IFR, applicable plans stil must cover vaccine administration fees (e.g.,
providers’ charges for their time, storage, recordkeeping, and supplies) without consumer cost
sharing.64 Per providers’ agreements with the CDC by which they are authorized to participate in
the COVID-19 vaccine program, they may bil payers—such as private insurance plans—for such
administration fees, but they may not bil patients for them.65
It is unclear to some observers whether consumer cost sharing may be possible in certain
circumstances, such as an office visit fee for a provider appointment at which administration of
the vaccine is not the primary purpose of the visit and depending on how the visit is bil ed (i.e.,
the circumstances for which certain cost sharing is al owable under existing preventive services
coverage regulations). For office visits involving COVID-19 vaccination, the November IFR
prohibits consumer cost sharing in the same circumstances for which it is prohibited under
existing preventive services coverage provisions. It is silent on whether cost sharing is conversely
al owable for office visits involving COVID-19 vaccination, when it is al owable for other
preventive services. No other potential fees (e.g., facility fees) are addressed in statute or
guidance, and the CDC rules on provider bil ing related to the vaccine also are silent on fees other
than a vaccine administration fee.
Out-of-Network Coverage
CARES Act Section 3202 does not address out-of-network coverage of the vaccine or related
costs but states that such coverage shal be “pursuant to PHSA Section 2713 and related
regulations.” PHSA Section 2713 coverage requirements general y do not apply out of network.
The November 2020 IFR, however, amends the relevant regulations to require COVID-19
vaccines and preventive services coverage without cost sharing, regardless of whether they are
provided in network or out of network.66 The IFR includes requirements for plans’ reimbursement
of out-of-network providers to be “reasonable, as determined in comparison to prevailing market
rates for such service.” These additional requirements apply only during the PHE period,
however; beyond the PHE period, the coverage requirements stil apply in network.
State and Private-Sector Actions
Some of the state and insurer announcements about coverage of COVID-19 benefits, discussed
earlier in this report, reference vaccine coverage.67 Even though the federal purchase of vaccines
is in effect across the U.S., consumers may stil find it useful to contact their insurers or plan
sponsors to understand their coverage of services and items related to the administration of the
vaccine.

and Support ,” updated January 7, 2021, at https://www.cdc.gov/vaccines/covid-19/vaccination-provider-support.html.
64 November 2020 IFR, beginning on page 71174.
65 See CRS Insight IN11609, COVID-19 Vaccine: Financing for Its Administration.
66 November IFR, page 71175.
67 See footnote 42. Besides the AHIP resource listed earlier, the organization now also has a list of insurer
announcements specific to COVID-19 vaccines: https://www.ahip.org/ensuring-access-to-covid-19-vaccines/.
Congressional Research Service
15

FAQ: COVID-19 and Private Health Insurance Coverage

Appendix. Resources for Questions About Private
Health Insurance and COVID-19-Related Services
This report has focused on coverage of COVID-19 testing, treatment, and vaccination by most
types of private health insurance plans. CRS analysts are also available to congressional clients to
discuss other topics of interest related to private health insurance and COVID-19, including
 coverage of COVID-19 benefits by types of private plans not specifical y
addressed in this report;
 other issues related to private coverage of COVID-19 benefits;
 private coverage of certain other benefits of concern during this pandemic, or of
services furnished via telehealth; and
 issues related to private health insurance enrollment and premium payments.
The following table lists examples of such topics of interest, any relevant legislative or
administrative resources, any relevant CRS resources, and names of appropriate CRS experts for
the benefit of congressional clients. Besides the CRS reports listed below that provide
background on relevant topics, also see CRS reports on health provisions in recent COVID-19
legislation and a CRS report that provides more detail on COVID-19 testing issues, including
private health insurance coverage:
 CRS Report R46316, Health Care Provisions in the Families First Coronavirus
Response Act, P.L. 116-127
 CRS Report R46334, Selected Health Provisions in Title III of the CARES Act
(P.L. 116-136)
 CRS Report R46481, COVID-19 Testing: Frequently Asked Questions
 CRS Insight IN11609, COVID-19 Vaccine: Financing for Its Administration
The information in this report is current as of its publication date and may be superseded by
subsequent congressional or administrative action. Congressional clients may contact the report
author and/or experts listed below for questions about further developments. In addition, CMS
guidance related to private health insurance and COVID-19 is compiled on its website.68

68 CMS, CCIIO, “Coronavirus Disease 2019 (COVID-19) Guidance,” accessed February 17, 2021, at
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs#COVID-19.
Congressional Research Service
16

link to page 19 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 link to page 21 FAQ: COVID-19 and Private Health Insurance Coverage

Table A-1. Resources for Further Questions About Private Health Insurance
FFCRA and CARES Act provisions are discussed in the reports listed in the Appendix

Key Federal Resources
CRS Resources
CRS Experts
Coverage of COVID-19 benefits by types of private plans not addressed in this report
Federal Employees
FFCRA §6006
CRS Report R43922, Federal
Noah Isserman
Health Benefits
Employees Health Benefits (FEHB)

(FEHB) Program
Program: An Overview
Catastrophic plans
CMS March 18 FAQa
CRS Report R44065, Overview of
Vanessa
Health Insurance Exchanges
Forsberg
Certain other health
Tri-Agency FAQ 42c
CRS Report R46003, Applicability of
Vanessa
coverage

Tri-Agency FAQ 43d
Federal Requirements to Selected Health
Forsberg
arrangementsb

Tri-Agency FAQ 44e
Coverage Arrangements
Other issues related to private coverage of COVID-19 benefits
Health savings account IRS March 11 Noticef
CRS Report R45277, Health Savings
Ryan Rosso
(HSA) eligibility and

CARES Act §3701 and
Accounts (HSAs)

high-deductible health
§3702
plans (HDHPs)
Out-of-network
Tri-Agency FAQ 42c
CRS Report R46116, Surprise Bil ing in
Ryan Rosso
coverage and surprise

Tri-Agency FAQ 43d
Private Health Insurance: Overview and
Noah Isserman
bil ing

Tri-Agency FAQ 44e
Federal Policy Considerations

HHS Provider Relief
Funding Terms and
Conditionsg

CARES Act §3202
Private coverage of certain benefits not addressed in this report
Mental health
Tri-Agency FAQ 43d
N/A
Noah Isserman
(coverage)

Johnathan Duff
(service provision)
Telehealth
CMS March 24 Telehealth
CRS Report R46239, Telehealth and
Noah Isserman
FAQh
Telemedicine: Frequently Asked Questions (coverage)

Tri-Agency FAQ 42c
Elayne Heisler
Tri-Agency FAQ 43d
(service provision)
Prescription drugs
CMS March 24
Consumer out-of-pocket drug costs
Noah Isserman
Prescription Drug FAQi
section of CRS Report R44832,

Frequently Asked Questions About
Prescription Drug Pricing and Policy
Private health insurance enrollment and premiums
Health insurance
Healthcare.gov COVID-
CRS Report R44065, Overview of
Vanessa
exchanges
19 pagej
Health Insurance Exchanges
Forsberg

Premium payments;
CMS March 24 Premium
CRS Report R44425, Health Insurance
Bernadette
premium tax credits
Payment FAQk
Premium Tax Credits and Cost-Sharing
Fernandez
and cost-sharing

CMS August 4 Premium
Subsidies

subsidies
Credit Guidancel
CRS Report R44392, The Health
Coverage Tax Credit (HCTC): In Brief
Congressional Research Service
17

FAQ: COVID-19 and Private Health Insurance Coverage

Key Federal Resources
CRS Resources
CRS Experts
Loss of employment-
N/A
CRS In Focus IF11523, Health
Ryan Rosso
based coverage

Insurance Options Fol owing Loss of

Employment

CRS Report R40142, Health Insurance

Continuation Coverage Under COBRA
Source: Created by CRS.
Notes: This table is not meant to represent a comprehensive list of topics related to private health insurance
coverage and COVID-19. “FFCRA” is the Families First Coronavirus Response Act. “CARES Act” is the
Coronavirus Aid, Relief, and Economic Security Act. “CMS” is the Centers for Medicare & Medicaid Services.
“IRS” is the Internal Revenue Service. “Tri-Agency” refers to the Departments of Labor (DOL), Health and
Human Services (HHS), and the Treasury.
a. CMS, “FAQs on Catastrophic Plan Coverage and the Coronavirus Disease 2019 (COVID-19),” March 18,
2020, at https://www.cms.gov/CCIIO/Resources/Files/Catastrophic-Coverage-of-COVID-19.pdf.
b. The Tri-Agency FAQ 42 notes the applicability of FFCRA requirements to certain types of plans not
addressed in this report, including nonfederal governmental plans, church plans, student plans, group health
plans covering fewer than two current employees (including “retiree plans”), and plans in their provision of
excepted benefits. It also addresses short-term, limited-duration insurance (STLDI). Background on some of
these coverage arrangements is provided in the CRS report noted above.
c. DOL, HHS, and Treasury, “FAQS About Families First Coronavirus Response Act and Coronavirus Aid,
Relief, and Economic Security Act Implementation, Part 42,” April 11, 2020, at https://www.cms.gov/files/
document/FFCRA-Part-42-FAQs.pdf.
d. DOL, HHS, and Treasury, “FAQS About Families First Coronavirus Response Act and Coronavirus Aid,
Relief, and Economic Security Act Implementation, Part 43,” June 23, 2020, at https://www.cms.gov/files/
document/FFCRA-Part-43-FAQs.pdf.
e. DOL, HHS, and Treasury, “FAQS About Families First Coronavirus Response Act and Coronavirus Aid,
Relief, and Economic Security Act Implementation, Part 44,” February 26, 2021, at https://www.cms.gov/
files/document/faqs-part-44.pdf.
f.
IRS, “HIGH DEDUCTIBLE HEALTH PLANS AND EXPENSES RELATED TO COVID-19,” March 11, 2020,
at https://www.irs.gov/pub/irs-drop/n-20-15.pdf.
g. HHS, “Acceptance of Terms and Conditions,” February 25, 2021, at https://www.hhs.gov/sites/default/files/
relief-fund-payment-terms-and-conditions.pdf.
h. CMS, “FAQs on Availability and Usage of Telehealth Services through Private Health Insurance Coverage in
Response to Coronavirus Disease 2019,” March 24, 2020, at https://www.cms.gov/files/document/faqs-
telehealth-covid-19.pdf.
i.
CMS, “FAQs on Prescription Drugs and the Coronavirus Disease 2019 (COVID-19) for Issuers Offering
Health Insurance Coverage in the Individual and Smal Group Markets,” March 24, 2020, at
https://www.cms.gov/files/document/faqs-rx-covid-19.pdf.
j.
Healthcare.gov, “Marketplace Coverage & Coronavirus,” accessed February 25, 2020, at
https://www.healthcare.gov/coronavirus/. In addition, some organizations are tracking state-based
exchanges’ decisions to open special enrol ment periods. For example, see National Association of
Insurance Commissioners (NAIC), “State Bul etins and Alerts,” “Life and Health Chart,” updated December
10, 2020, at https://content.naic.org/naic_coronavirus_info.htm.
k. CMS, “Payment and Grace Period Flexibilities Associated with the COVID-19 National Emergency,” March
24, 2020, at https://www.cms.gov/files/document/faqs-payment-and-grace-period-covid-19.pdf.
l.
CMS, “Temporary Policy on 2020 Premium Credits Associated with the COVID-19 Public Health
Emergency,” August 4, 2020, at https://www.cms.gov/CCIIO/Programs-and-Initiatives/Health-Insurance-
Marketplaces/Downloads/Premium-Credit-Guidance.pdf.

Congressional Research Service
18

FAQ: COVID-19 and Private Health Insurance Coverage

Author Information

Vanessa C. Forsberg

Analyst in Health Care Financing

Acknowledgments
Multiple CRS analysts provided review and comments on this report, or wrote content in other reports that
was adapted or cited for this one, including Bernadette Fernandez, Sarah A. Lister, Ryan Rosso, Kavya
Sekar, Noah Isserman, Amanda K. Sarata, Agata Dabrowska, Johnathan Duff, Victoria L. Elliott, and
Jennifer A. Staman.

Disclaimer
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan
shared staff to congressional committees and Members of Congress. It operates solely at the behest of and
under the direction of Congress. Information in a CRS Report should n ot be relied upon for purposes other
than public understanding of information that has been provided by CRS to Members of Congress in
connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not
subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in
its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or
material from a third party, you may need to obtain the permission of the copyright holder if you wish to
copy or otherwise use copyrighted material.

Congressional Research Service
R46359 · VERSION 4 · UPDATED
19

Download PDF

Download EPUB

Revision History

Apr. 9, 2021

HTML · PDF

8% changed

Aug. 24, 2020

HTML · PDF

17% changed

May. 15, 2020

HTML · PDF

Metadata